Skandinaviska Enskilda Banken AB publ Sells 32,500 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Skandinaviska Enskilda Banken AB publ lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 77.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,500 shares of the medical equipment provider's stock after selling 32,500 shares during the quarter. Skandinaviska Enskilda Banken AB publ's holdings in Lantheus were worth $847,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in LNTH. Atria Investments Inc bought a new stake in shares of Lantheus in the 3rd quarter worth about $330,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in Lantheus in the third quarter worth about $728,000. Victory Capital Management Inc. increased its holdings in Lantheus by 198.9% in the third quarter. Victory Capital Management Inc. now owns 76,833 shares of the medical equipment provider's stock valued at $8,432,000 after buying an additional 51,128 shares during the last quarter. Huntington National Bank raised its stake in Lantheus by 161.2% during the third quarter. Huntington National Bank now owns 1,946 shares of the medical equipment provider's stock valued at $214,000 after buying an additional 1,201 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new position in Lantheus during the 3rd quarter worth approximately $222,000. Institutional investors own 99.06% of the company's stock.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock valued at $6,110,806 over the last ninety days. Insiders own 1.50% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms recently issued reports on LNTH. The Goldman Sachs Group initiated coverage on Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $1.14 during mid-day trading on Friday, reaching $97.71. 1,059,977 shares of the company traded hands, compared to its average volume of 935,974. Lantheus Holdings, Inc. has a fifty-two week low of $57.92 and a fifty-two week high of $126.89. The firm has a market cap of $6.69 billion, a PE ratio of 16.26 and a beta of 0.38. The stock has a fifty day simple moving average of $92.64 and a 200-day simple moving average of $96.70.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.